A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-12

AUTHORS

Adam Platt, John Morten, Qunsheng Ji, Paul Elvin, Chris Womack, Xinying Su, Emma Donald, Neil Gray, Jessica Read, Graham Bigley, Laura Blockley, Carl Cresswell, Angela Dale, Amanda Davies, Tianwei Zhang, Shuqiong Fan, Haihua Fu, Amanda Gladwin, Grace Harrod, James Stevens, Victoria Williams, Qingqing Ye, Li Zheng, Richard de Boer, Roy S Herbst, Jin-Soo Lee, James Vasselli

ABSTRACT

BACKGROUND: To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome to vandetanib treatment. METHODS: Archival tumor samples from the ZODIAC ( NCT00312377 , vandetanib ± docetaxel), ZEAL ( NCT00418886 , vandetanib ± pemetrexed), ZEPHYR ( NCT00404924 , vandetanib vs placebo) and ZEST ( NCT00364351 , vandetanib vs erlotinib) studies were evaluated by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 944 and 1102 patients. RESULTS: The prevalence of RET rearrangements by FISH was 0.7% (95% CI 0.3-1.5%) among patients with a known result. Seven tumor samples were positive for RET rearrangements (vandetanib, n = 3; comparator, n = 4). 2.8% (n = 26) of samples had RET amplification (innumerable RET clusters, or ≥7 copies in > 10% of tumor cells), 8.1% (n = 76) had low RET gene copy number gain (4-6 copies in ≥40% of tumor cells) and 8.3% (n = 92) were RET expression positive (signal intensity ++ or +++ in >10% of tumor cells). Of RET-rearrangement-positive patients, none had an objective response in the vandetanib arm and one patient responded in the comparator arm. Radiologic evidence of tumor shrinkage was observed in two patients treated with vandetanib and one treated with comparator drug. The objective response rate was similar in the vandetanib and comparator arms for patients positive for RET copy number gains or RET protein expression. CONCLUSIONS: We have identified prevalence for three RET biomarkers in a population predominated by non-Asians and smokers. RET rearrangement prevalence was lower than previously reported. We found no evidence of a differential benefit for efficacy by IHC and RET gene copy number gains. The low prevalence of RET rearrangements (0.7%) prevents firm conclusions regarding association of vandetanib treatment with efficacy in the RET rearrangement NSCLC subpopulation. TRIAL REGISTRATION: Randomized Phase III clinical trials ( NCT00312377 , ZODIAC; NCT00418886 , ZEAL; NCT00364351 , ZEST; NCT00404924 , ZEPHYR). More... »

PAGES

171

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8

DOI

http://dx.doi.org/10.1186/s12885-015-1146-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1014779199

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25881079


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Amplification", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prevalence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-ret", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Translocation, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, da Vinci Building, Melbourn Science Park, Cambridge Road, Melbourn, SG8 6HB, Royston, Hertfordshire, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Platt", 
        "givenName": "Adam", 
        "id": "sg:person.01034244476.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034244476.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morten", 
        "givenName": "John", 
        "id": "sg:person.014307457674.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014307457674.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ji", 
        "givenName": "Qunsheng", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Elvin", 
        "givenName": "Paul", 
        "id": "sg:person.01125017710.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125017710.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Womack", 
        "givenName": "Chris", 
        "id": "sg:person.01173133110.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173133110.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Su", 
        "givenName": "Xinying", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Donald", 
        "givenName": "Emma", 
        "id": "sg:person.01253601301.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253601301.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gray", 
        "givenName": "Neil", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Read", 
        "givenName": "Jessica", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bigley", 
        "givenName": "Graham", 
        "id": "sg:person.01225342041.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225342041.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blockley", 
        "givenName": "Laura", 
        "id": "sg:person.01050462340.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050462340.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cresswell", 
        "givenName": "Carl", 
        "id": "sg:person.0662375405.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662375405.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dale", 
        "givenName": "Angela", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davies", 
        "givenName": "Amanda", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Tianwei", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fan", 
        "givenName": "Shuqiong", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fu", 
        "givenName": "Haihua", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gladwin", 
        "givenName": "Amanda", 
        "id": "sg:person.01266635025.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266635025.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harrod", 
        "givenName": "Grace", 
        "id": "sg:person.01241656537.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241656537.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stevens", 
        "givenName": "James", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Williams", 
        "givenName": "Victoria", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ye", 
        "givenName": "Qingqing", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Innovation Cancer Center, AstraZeneca R&D, Shanghai, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zheng", 
        "givenName": "Li", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Western Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417075.0", 
          "name": [
            "Department of Hematology & Medical Oncology, Western Hospital, Melbourne, Victoria, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Boer", 
        "givenName": "Richard", 
        "id": "sg:person.0636147734.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636147734.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.433818.5", 
          "name": [
            "Yale Comprehensive Cancer Center, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Herbst", 
        "givenName": "Roy S", 
        "id": "sg:person.01150737671.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150737671.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.410914.9", 
          "name": [
            "National Cancer Center, Goyang, Republic of Korea"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Jin-Soo", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "AstraZeneca, Wilmington, DE, USA", 
            "Current address \u2013 MedImmune, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vasselli", 
        "givenName": "James", 
        "id": "sg:person.01310421443.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310421443.70"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2010.28.5981", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000100366"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2013.07.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001739222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2013.07.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001739222"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e31828a4d07", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001925332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-0838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002158930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-0838", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002158930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/cr.2012.27", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004383808", 
          "https://doi.org/10.1038/cr.2012.27"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.27940", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005873179"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2159-8290.cd-13-0035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006314777"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2159-8290.cd-13-0035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006314777"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.42.9829", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008924255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.29.5717", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013535496"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.36.1709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014560769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.1477", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015188906"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.1477", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015188906"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.91.4.1579", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019071287"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/363458a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019766488", 
          "https://doi.org/10.1038/363458a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2673", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028758097", 
          "https://doi.org/10.1038/nm.2673"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3182721ed1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032942774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034280993", 
          "https://doi.org/10.1038/nm.2644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034280993", 
          "https://doi.org/10.1038/nm.2644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034280993", 
          "https://doi.org/10.1038/nm.2644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2644", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034280993", 
          "https://doi.org/10.1038/nm.2644"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2658", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040612411", 
          "https://doi.org/10.1038/nm.2658"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2658", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040612411", 
          "https://doi.org/10.1038/nm.2658"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cam4.13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041196518"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1101/gr.133645.111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041486412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-12-3898", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047932956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(10)70132-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052718381"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/hmg/2.7.851", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059644513"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2007-1714", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064290203"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.2012.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071531954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/or.2012.1908", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071531954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075108930", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075208258", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076464895", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-12", 
    "datePublishedReg": "2015-12-01", 
    "description": "BACKGROUND: To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome to vandetanib treatment.\nMETHODS: Archival tumor samples from the ZODIAC ( NCT00312377 , vandetanib \u00b1 docetaxel), ZEAL ( NCT00418886 , vandetanib \u00b1 pemetrexed), ZEPHYR ( NCT00404924 , vandetanib vs placebo) and ZEST ( NCT00364351 , vandetanib vs erlotinib) studies were evaluated by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 944 and 1102 patients.\nRESULTS: The prevalence of RET rearrangements by FISH was 0.7% (95% CI 0.3-1.5%) among patients with a known result. Seven tumor samples were positive for RET rearrangements (vandetanib, n = 3; comparator, n = 4). 2.8% (n = 26) of samples had RET amplification (innumerable RET clusters, or \u22657 copies in > 10% of tumor cells), 8.1% (n = 76) had low RET gene copy number gain (4-6 copies in \u226540% of tumor cells) and 8.3% (n = 92) were RET expression positive (signal intensity ++ or +++ in >10% of tumor cells). Of RET-rearrangement-positive patients, none had an objective response in the vandetanib arm and one patient responded in the comparator arm. Radiologic evidence of tumor shrinkage was observed in two patients treated with vandetanib and one treated with comparator drug. The objective response rate was similar in the vandetanib and comparator arms for patients positive for RET copy number gains or RET protein expression.\nCONCLUSIONS: We have identified prevalence for three RET biomarkers in a population predominated by non-Asians and smokers. RET rearrangement prevalence was lower than previously reported. We found no evidence of a differential benefit for efficacy by IHC and RET gene copy number gains. The low prevalence of RET rearrangements (0.7%) prevents firm conclusions regarding association of vandetanib treatment with efficacy in the RET rearrangement NSCLC subpopulation.\nTRIAL REGISTRATION: Randomized Phase III clinical trials ( NCT00312377 , ZODIAC; NCT00418886 , ZEAL; NCT00364351 , ZEST; NCT00404924 , ZEPHYR).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-015-1146-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies", 
    "pagination": "171", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "46696ef0d0027c39820e277359a9a86385a22fa4eb2da8308fc04fe3d0941221"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25881079"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-015-1146-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1014779199"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-015-1146-8", 
      "https://app.dimensions.ai/details/publication/pub.1014779199"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:57", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89807_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2Fs12885-015-1146-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-015-1146-8'


 

This table displays all metadata directly associated to this object as RDF triples.

407 TRIPLES      21 PREDICATES      71 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-015-1146-8 schema:about N01115868df16443abd8c4b18e0831580
2 N0fe22f0b8735424d8a0c7b72fc5a8157
3 N1baccd2e7f184dd591fe61ce3e3172cd
4 N1d1986816090407c81f511429eb59cad
5 N2a35a5547490480f833df1d0dde29b84
6 N3a7ffabab1404a91bf1646131b6d56b2
7 N4f9a88bca17a40a1a536d81ec11e9a2f
8 N60d977a509ad4df794e4f1b23dd83c67
9 N830cb8707e1949988db7414c0943e531
10 Na25964910453428f87878b9f555cd225
11 Na3c611f3fee84ab0a852e6baff2c45d4
12 Nbcfea72881e44a6e8f1360f5530b3a75
13 Ndb3d9061e17b4e7394ac2a556eef815f
14 Ne1add1310dee47989f3e7f000cf8eadb
15 Nf0c2440bc3d047e48f99b810ada4f36f
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N7d2fdd386b9c4d048bbd44b0250fe04e
19 schema:citation sg:pub.10.1038/363458a0
20 sg:pub.10.1038/cr.2012.27
21 sg:pub.10.1038/nm.2644
22 sg:pub.10.1038/nm.2658
23 sg:pub.10.1038/nm.2673
24 https://app.dimensions.ai/details/publication/pub.1075108930
25 https://app.dimensions.ai/details/publication/pub.1075208258
26 https://app.dimensions.ai/details/publication/pub.1076464895
27 https://doi.org/10.1002/cam4.13
28 https://doi.org/10.1002/cncr.27940
29 https://doi.org/10.1016/j.lungcan.2013.07.009
30 https://doi.org/10.1016/s1470-2045(10)70132-7
31 https://doi.org/10.1073/pnas.91.4.1579
32 https://doi.org/10.1093/hmg/2.7.851
33 https://doi.org/10.1097/jto.0b013e3182721ed1
34 https://doi.org/10.1097/jto.0b013e31828a4d07
35 https://doi.org/10.1101/gr.133645.111
36 https://doi.org/10.1158/1078-0432.ccr-12-0838
37 https://doi.org/10.1158/1078-0432.ccr-12-3898
38 https://doi.org/10.1158/2159-8290.cd-13-0035
39 https://doi.org/10.1200/jco.2010.28.5981
40 https://doi.org/10.1200/jco.2010.29.5717
41 https://doi.org/10.1200/jco.2011.36.1709
42 https://doi.org/10.1200/jco.2012.42.9829
43 https://doi.org/10.1200/jco.2012.44.1477
44 https://doi.org/10.1210/jc.2007-1714
45 https://doi.org/10.3892/or.2012.1908
46 schema:datePublished 2015-12
47 schema:datePublishedReg 2015-12-01
48 schema:description BACKGROUND: To determine the prevalence of RET rearrangement genes, RET copy number gains and expression in tumor samples from four Phase III non-small-cell lung cancer (NSCLC) trials of vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling, and to determine any association with outcome to vandetanib treatment. METHODS: Archival tumor samples from the ZODIAC ( NCT00312377 , vandetanib ± docetaxel), ZEAL ( NCT00418886 , vandetanib ± pemetrexed), ZEPHYR ( NCT00404924 , vandetanib vs placebo) and ZEST ( NCT00364351 , vandetanib vs erlotinib) studies were evaluated by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in 944 and 1102 patients. RESULTS: The prevalence of RET rearrangements by FISH was 0.7% (95% CI 0.3-1.5%) among patients with a known result. Seven tumor samples were positive for RET rearrangements (vandetanib, n = 3; comparator, n = 4). 2.8% (n = 26) of samples had RET amplification (innumerable RET clusters, or ≥7 copies in > 10% of tumor cells), 8.1% (n = 76) had low RET gene copy number gain (4-6 copies in ≥40% of tumor cells) and 8.3% (n = 92) were RET expression positive (signal intensity ++ or +++ in >10% of tumor cells). Of RET-rearrangement-positive patients, none had an objective response in the vandetanib arm and one patient responded in the comparator arm. Radiologic evidence of tumor shrinkage was observed in two patients treated with vandetanib and one treated with comparator drug. The objective response rate was similar in the vandetanib and comparator arms for patients positive for RET copy number gains or RET protein expression. CONCLUSIONS: We have identified prevalence for three RET biomarkers in a population predominated by non-Asians and smokers. RET rearrangement prevalence was lower than previously reported. We found no evidence of a differential benefit for efficacy by IHC and RET gene copy number gains. The low prevalence of RET rearrangements (0.7%) prevents firm conclusions regarding association of vandetanib treatment with efficacy in the RET rearrangement NSCLC subpopulation. TRIAL REGISTRATION: Randomized Phase III clinical trials ( NCT00312377 , ZODIAC; NCT00418886 , ZEAL; NCT00364351 , ZEST; NCT00404924 , ZEPHYR).
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree true
52 schema:isPartOf N4c0dbae69825444daaa4c67932efad7d
53 Nf0b0ecf3aec44f67bab4df911f6bfa56
54 sg:journal.1024632
55 schema:name A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies
56 schema:pagination 171
57 schema:productId N0d93e79b05764bf6b9bed2ef34a918a1
58 N45c82347e7584371ac135456aa291f76
59 N4f9f92f893164e30b8b5dd5cb57fe278
60 Ne39531a35fe043b5bb2d7604a6cfe44f
61 Ne3c3cdd0708342cbb5de8afe124d73c0
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014779199
63 https://doi.org/10.1186/s12885-015-1146-8
64 schema:sdDatePublished 2019-04-11T09:57
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher Na91e4669edb648a690b64beba678352e
67 schema:url http://link.springer.com/10.1186%2Fs12885-015-1146-8
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N00b5d2fd00fb4917bab43203d1120a97 rdf:first N859aaf1fa99143139fc5010f6ea38631
72 rdf:rest Na8f2f2b88b0642dca525c60707cda62e
73 N01115868df16443abd8c4b18e0831580 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Gene Amplification
75 rdf:type schema:DefinedTerm
76 N08d85ff582214889a84e8cb7332785e3 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
77 rdf:type schema:Organization
78 N0d93e79b05764bf6b9bed2ef34a918a1 schema:name readcube_id
79 schema:value 46696ef0d0027c39820e277359a9a86385a22fa4eb2da8308fc04fe3d0941221
80 rdf:type schema:PropertyValue
81 N0fa9fee7afa4483fac5ca8ceadd9d5de rdf:first N158bc107efc042e29a44c2e52000507a
82 rdf:rest N67bf7c03486042599c56f069ebe6f434
83 N0fe22f0b8735424d8a0c7b72fc5a8157 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Male
85 rdf:type schema:DefinedTerm
86 N129634f28cc34e86b9c5fdfb110e73cf schema:affiliation Ncad8c8dff0a3427e952de7c3800717ee
87 schema:familyName Su
88 schema:givenName Xinying
89 rdf:type schema:Person
90 N158bc107efc042e29a44c2e52000507a schema:affiliation https://www.grid.ac/institutes/grid.417815.e
91 schema:familyName Read
92 schema:givenName Jessica
93 rdf:type schema:Person
94 N1baccd2e7f184dd591fe61ce3e3172cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Quinazolines
96 rdf:type schema:DefinedTerm
97 N1d1986816090407c81f511429eb59cad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Aged
99 rdf:type schema:DefinedTerm
100 N2452c7dae6174c0196371adcba32a6a5 rdf:first sg:person.01266635025.79
101 rdf:rest N35d506e2d9834dbeb064065997ff9c70
102 N2a35a5547490480f833df1d0dde29b84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Middle Aged
104 rdf:type schema:DefinedTerm
105 N3338a769f3bc454d85454bb1aab49398 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
106 rdf:type schema:Organization
107 N35d506e2d9834dbeb064065997ff9c70 rdf:first sg:person.01241656537.88
108 rdf:rest Nb2e7c2fdd7434fffa66fab9b70fa9344
109 N3a7ffabab1404a91bf1646131b6d56b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Humans
111 rdf:type schema:DefinedTerm
112 N3e913190f91e4915a8a49c95e2eb1bf2 schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
113 rdf:type schema:Organization
114 N435da71310c7431197fe59834a47931f schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
115 rdf:type schema:Organization
116 N45c82347e7584371ac135456aa291f76 schema:name pubmed_id
117 schema:value 25881079
118 rdf:type schema:PropertyValue
119 N4c0dbae69825444daaa4c67932efad7d schema:volumeNumber 15
120 rdf:type schema:PublicationVolume
121 N4f9a88bca17a40a1a536d81ec11e9a2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Treatment Outcome
123 rdf:type schema:DefinedTerm
124 N4f9f92f893164e30b8b5dd5cb57fe278 schema:name nlm_unique_id
125 schema:value 100967800
126 rdf:type schema:PropertyValue
127 N5833a71a6a0d4c28bad12710e839e477 rdf:first Ndac4ec5729bd4b33bec91be2114cab11
128 rdf:rest Nc4ae32b4204447bfa0b55a30f2df16e7
129 N5c48edb7710243b9bd7fa23dd177ae4d schema:affiliation N85377e14ded342aa8b9961ccf7052bed
130 schema:familyName Fu
131 schema:givenName Haihua
132 rdf:type schema:Person
133 N60d977a509ad4df794e4f1b23dd83c67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Lung Neoplasms
135 rdf:type schema:DefinedTerm
136 N63ccb9867d194e2d89b3541f5b487489 rdf:first sg:person.014307457674.87
137 rdf:rest Nc717525895fc43d082c58508390b9e28
138 N67b4464e7ed64c1f8934fd0d58add4aa rdf:first N5c48edb7710243b9bd7fa23dd177ae4d
139 rdf:rest N2452c7dae6174c0196371adcba32a6a5
140 N67bf7c03486042599c56f069ebe6f434 rdf:first sg:person.01225342041.57
141 rdf:rest Nb03d1e20171040e6b5c4a785350a4c3a
142 N7a9c27e8658e4a98a42b478b3768cd35 rdf:first sg:person.01173133110.53
143 rdf:rest Ndd915363399840ff8daab64374b8f0a7
144 N7b7ffde26adf486fbed918d5953a86b0 schema:affiliation N3e913190f91e4915a8a49c95e2eb1bf2
145 schema:familyName Fan
146 schema:givenName Shuqiong
147 rdf:type schema:Person
148 N7d2fdd386b9c4d048bbd44b0250fe04e rdf:first sg:person.01034244476.04
149 rdf:rest N63ccb9867d194e2d89b3541f5b487489
150 N830cb8707e1949988db7414c0943e531 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Retrospective Studies
152 rdf:type schema:DefinedTerm
153 N85377e14ded342aa8b9961ccf7052bed schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
154 rdf:type schema:Organization
155 N859aaf1fa99143139fc5010f6ea38631 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
156 schema:familyName Davies
157 schema:givenName Amanda
158 rdf:type schema:Person
159 N89340e8860f943259ce3a369fbe37925 rdf:first N9aa61d11fa6349b59365074c0b2906a0
160 rdf:rest N5833a71a6a0d4c28bad12710e839e477
161 N9387f693054343fb80ee41e169c76f4b rdf:first sg:person.01253601301.22
162 rdf:rest Nfc65b0ad8d7a46c7827aad1adc4a26d0
163 N9751bd82af6f4686a34877d324227e53 schema:affiliation N3338a769f3bc454d85454bb1aab49398
164 schema:familyName Zheng
165 schema:givenName Li
166 rdf:type schema:Person
167 N9aa61d11fa6349b59365074c0b2906a0 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
168 schema:familyName Williams
169 schema:givenName Victoria
170 rdf:type schema:Person
171 N9d83dc2556264fd1af4866968f9dd89f rdf:first N7b7ffde26adf486fbed918d5953a86b0
172 rdf:rest N67b4464e7ed64c1f8934fd0d58add4aa
173 Na25964910453428f87878b9f555cd225 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Proto-Oncogene Proteins c-ret
175 rdf:type schema:DefinedTerm
176 Na3c611f3fee84ab0a852e6baff2c45d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Female
178 rdf:type schema:DefinedTerm
179 Na8f2f2b88b0642dca525c60707cda62e rdf:first Nfacd2a5bf9b44932a46f095d3ee316d7
180 rdf:rest N9d83dc2556264fd1af4866968f9dd89f
181 Na91e4669edb648a690b64beba678352e schema:name Springer Nature - SN SciGraph project
182 rdf:type schema:Organization
183 Nabb694e5e8b04cbeb90b837136ea4292 rdf:first sg:person.01125017710.16
184 rdf:rest N7a9c27e8658e4a98a42b478b3768cd35
185 Nb03d1e20171040e6b5c4a785350a4c3a rdf:first sg:person.01050462340.23
186 rdf:rest Nee9d1bfdf1c44d4593559b675b627cf6
187 Nb2e7c2fdd7434fffa66fab9b70fa9344 rdf:first Nddb207167e9f469fbca266243809f55b
188 rdf:rest N89340e8860f943259ce3a369fbe37925
189 Nb39d5aef1bc1418b96eea9fd7da66c92 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
190 schema:familyName Gray
191 schema:givenName Neil
192 rdf:type schema:Person
193 Nbcfea72881e44a6e8f1360f5530b3a75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Piperidines
195 rdf:type schema:DefinedTerm
196 Nc406b04fed104ee69515992d6fa186e1 rdf:first sg:person.01310421443.70
197 rdf:rest rdf:nil
198 Nc4ae32b4204447bfa0b55a30f2df16e7 rdf:first N9751bd82af6f4686a34877d324227e53
199 rdf:rest Nfa1b7522e8ba43b5b025ef2cb4ae24a2
200 Nc709bf1f03034c2987672a64635722fd schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
201 rdf:type schema:Organization
202 Nc717525895fc43d082c58508390b9e28 rdf:first Nf8d4eac9a05842a9ad29a99bf276e19a
203 rdf:rest Nabb694e5e8b04cbeb90b837136ea4292
204 Ncac6f3add8534dd7929829d4a2bfd6e6 rdf:first Ndb0f8cdd4f374eb58439fb459a1816cb
205 rdf:rest Nc406b04fed104ee69515992d6fa186e1
206 Ncad8c8dff0a3427e952de7c3800717ee schema:name Innovation Cancer Center, AstraZeneca R&D, Shanghai, China
207 rdf:type schema:Organization
208 Ncfb390db83714a61bc04904935dd5dbb schema:affiliation https://www.grid.ac/institutes/grid.417815.e
209 schema:familyName Dale
210 schema:givenName Angela
211 rdf:type schema:Person
212 Ndac4ec5729bd4b33bec91be2114cab11 schema:affiliation N435da71310c7431197fe59834a47931f
213 schema:familyName Ye
214 schema:givenName Qingqing
215 rdf:type schema:Person
216 Ndb0f8cdd4f374eb58439fb459a1816cb schema:affiliation https://www.grid.ac/institutes/grid.410914.9
217 schema:familyName Lee
218 schema:givenName Jin-Soo
219 rdf:type schema:Person
220 Ndb3d9061e17b4e7394ac2a556eef815f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
221 schema:name Translocation, Genetic
222 rdf:type schema:DefinedTerm
223 Ndd915363399840ff8daab64374b8f0a7 rdf:first N129634f28cc34e86b9c5fdfb110e73cf
224 rdf:rest N9387f693054343fb80ee41e169c76f4b
225 Nddb207167e9f469fbca266243809f55b schema:affiliation https://www.grid.ac/institutes/grid.417815.e
226 schema:familyName Stevens
227 schema:givenName James
228 rdf:type schema:Person
229 Ne1add1310dee47989f3e7f000cf8eadb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
230 schema:name Carcinoma, Non-Small-Cell Lung
231 rdf:type schema:DefinedTerm
232 Ne39531a35fe043b5bb2d7604a6cfe44f schema:name dimensions_id
233 schema:value pub.1014779199
234 rdf:type schema:PropertyValue
235 Ne3c3cdd0708342cbb5de8afe124d73c0 schema:name doi
236 schema:value 10.1186/s12885-015-1146-8
237 rdf:type schema:PropertyValue
238 Nee9d1bfdf1c44d4593559b675b627cf6 rdf:first sg:person.0662375405.84
239 rdf:rest Nf40edce933ba4e38bbe2ccb62ed9949f
240 Nef36900b8bab4eb2ac4fa364fdd5e11e rdf:first sg:person.01150737671.46
241 rdf:rest Ncac6f3add8534dd7929829d4a2bfd6e6
242 Nf0b0ecf3aec44f67bab4df911f6bfa56 schema:issueNumber 1
243 rdf:type schema:PublicationIssue
244 Nf0c2440bc3d047e48f99b810ada4f36f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
245 schema:name Prevalence
246 rdf:type schema:DefinedTerm
247 Nf40edce933ba4e38bbe2ccb62ed9949f rdf:first Ncfb390db83714a61bc04904935dd5dbb
248 rdf:rest N00b5d2fd00fb4917bab43203d1120a97
249 Nf8d4eac9a05842a9ad29a99bf276e19a schema:affiliation Nc709bf1f03034c2987672a64635722fd
250 schema:familyName Ji
251 schema:givenName Qunsheng
252 rdf:type schema:Person
253 Nfa1b7522e8ba43b5b025ef2cb4ae24a2 rdf:first sg:person.0636147734.20
254 rdf:rest Nef36900b8bab4eb2ac4fa364fdd5e11e
255 Nfacd2a5bf9b44932a46f095d3ee316d7 schema:affiliation N08d85ff582214889a84e8cb7332785e3
256 schema:familyName Zhang
257 schema:givenName Tianwei
258 rdf:type schema:Person
259 Nfc65b0ad8d7a46c7827aad1adc4a26d0 rdf:first Nb39d5aef1bc1418b96eea9fd7da66c92
260 rdf:rest N0fa9fee7afa4483fac5ca8ceadd9d5de
261 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
262 schema:name Medical and Health Sciences
263 rdf:type schema:DefinedTerm
264 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
265 schema:name Oncology and Carcinogenesis
266 rdf:type schema:DefinedTerm
267 sg:journal.1024632 schema:issn 1471-2407
268 schema:name BMC Cancer
269 rdf:type schema:Periodical
270 sg:person.01034244476.04 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
271 schema:familyName Platt
272 schema:givenName Adam
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034244476.04
274 rdf:type schema:Person
275 sg:person.01050462340.23 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
276 schema:familyName Blockley
277 schema:givenName Laura
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050462340.23
279 rdf:type schema:Person
280 sg:person.01125017710.16 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
281 schema:familyName Elvin
282 schema:givenName Paul
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125017710.16
284 rdf:type schema:Person
285 sg:person.01150737671.46 schema:affiliation https://www.grid.ac/institutes/grid.433818.5
286 schema:familyName Herbst
287 schema:givenName Roy S
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150737671.46
289 rdf:type schema:Person
290 sg:person.01173133110.53 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
291 schema:familyName Womack
292 schema:givenName Chris
293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173133110.53
294 rdf:type schema:Person
295 sg:person.01225342041.57 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
296 schema:familyName Bigley
297 schema:givenName Graham
298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01225342041.57
299 rdf:type schema:Person
300 sg:person.01241656537.88 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
301 schema:familyName Harrod
302 schema:givenName Grace
303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241656537.88
304 rdf:type schema:Person
305 sg:person.01253601301.22 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
306 schema:familyName Donald
307 schema:givenName Emma
308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01253601301.22
309 rdf:type schema:Person
310 sg:person.01266635025.79 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
311 schema:familyName Gladwin
312 schema:givenName Amanda
313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266635025.79
314 rdf:type schema:Person
315 sg:person.01310421443.70 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
316 schema:familyName Vasselli
317 schema:givenName James
318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310421443.70
319 rdf:type schema:Person
320 sg:person.014307457674.87 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
321 schema:familyName Morten
322 schema:givenName John
323 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014307457674.87
324 rdf:type schema:Person
325 sg:person.0636147734.20 schema:affiliation https://www.grid.ac/institutes/grid.417075.0
326 schema:familyName de Boer
327 schema:givenName Richard
328 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636147734.20
329 rdf:type schema:Person
330 sg:person.0662375405.84 schema:affiliation https://www.grid.ac/institutes/grid.417815.e
331 schema:familyName Cresswell
332 schema:givenName Carl
333 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662375405.84
334 rdf:type schema:Person
335 sg:pub.10.1038/363458a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019766488
336 https://doi.org/10.1038/363458a0
337 rdf:type schema:CreativeWork
338 sg:pub.10.1038/cr.2012.27 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004383808
339 https://doi.org/10.1038/cr.2012.27
340 rdf:type schema:CreativeWork
341 sg:pub.10.1038/nm.2644 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034280993
342 https://doi.org/10.1038/nm.2644
343 rdf:type schema:CreativeWork
344 sg:pub.10.1038/nm.2658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040612411
345 https://doi.org/10.1038/nm.2658
346 rdf:type schema:CreativeWork
347 sg:pub.10.1038/nm.2673 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028758097
348 https://doi.org/10.1038/nm.2673
349 rdf:type schema:CreativeWork
350 https://app.dimensions.ai/details/publication/pub.1075108930 schema:CreativeWork
351 https://app.dimensions.ai/details/publication/pub.1075208258 schema:CreativeWork
352 https://app.dimensions.ai/details/publication/pub.1076464895 schema:CreativeWork
353 https://doi.org/10.1002/cam4.13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041196518
354 rdf:type schema:CreativeWork
355 https://doi.org/10.1002/cncr.27940 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005873179
356 rdf:type schema:CreativeWork
357 https://doi.org/10.1016/j.lungcan.2013.07.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001739222
358 rdf:type schema:CreativeWork
359 https://doi.org/10.1016/s1470-2045(10)70132-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052718381
360 rdf:type schema:CreativeWork
361 https://doi.org/10.1073/pnas.91.4.1579 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019071287
362 rdf:type schema:CreativeWork
363 https://doi.org/10.1093/hmg/2.7.851 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059644513
364 rdf:type schema:CreativeWork
365 https://doi.org/10.1097/jto.0b013e3182721ed1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032942774
366 rdf:type schema:CreativeWork
367 https://doi.org/10.1097/jto.0b013e31828a4d07 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001925332
368 rdf:type schema:CreativeWork
369 https://doi.org/10.1101/gr.133645.111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041486412
370 rdf:type schema:CreativeWork
371 https://doi.org/10.1158/1078-0432.ccr-12-0838 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002158930
372 rdf:type schema:CreativeWork
373 https://doi.org/10.1158/1078-0432.ccr-12-3898 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047932956
374 rdf:type schema:CreativeWork
375 https://doi.org/10.1158/2159-8290.cd-13-0035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006314777
376 rdf:type schema:CreativeWork
377 https://doi.org/10.1200/jco.2010.28.5981 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000100366
378 rdf:type schema:CreativeWork
379 https://doi.org/10.1200/jco.2010.29.5717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013535496
380 rdf:type schema:CreativeWork
381 https://doi.org/10.1200/jco.2011.36.1709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014560769
382 rdf:type schema:CreativeWork
383 https://doi.org/10.1200/jco.2012.42.9829 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008924255
384 rdf:type schema:CreativeWork
385 https://doi.org/10.1200/jco.2012.44.1477 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015188906
386 rdf:type schema:CreativeWork
387 https://doi.org/10.1210/jc.2007-1714 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064290203
388 rdf:type schema:CreativeWork
389 https://doi.org/10.3892/or.2012.1908 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071531954
390 rdf:type schema:CreativeWork
391 https://www.grid.ac/institutes/grid.410914.9 schema:alternateName National Cancer Center
392 schema:name National Cancer Center, Goyang, Republic of Korea
393 rdf:type schema:Organization
394 https://www.grid.ac/institutes/grid.417075.0 schema:alternateName Western Hospital
395 schema:name Department of Hematology & Medical Oncology, Western Hospital, Melbourne, Victoria, Australia
396 rdf:type schema:Organization
397 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
398 schema:name AstraZeneca, Macclesfield, UK
399 AstraZeneca, da Vinci Building, Melbourn Science Park, Cambridge Road, Melbourn, SG8 6HB, Royston, Hertfordshire, UK
400 rdf:type schema:Organization
401 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
402 schema:name AstraZeneca, Wilmington, DE, USA
403 Current address – MedImmune, Gaithersburg, MD, USA
404 rdf:type schema:Organization
405 https://www.grid.ac/institutes/grid.433818.5 schema:alternateName Yale Cancer Center
406 schema:name Yale Comprehensive Cancer Center, New Haven, CT, USA
407 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...